Clinical outcome of FLAG-IDA chemotherapy sequential with Flu–Bu3 conditioning regimen in patients with refractory AML: a parallel study from Shanghai Institute of Hematology and Institut Paoli-Calmettes
Sign Up to like & getrecommendations! Published in 2018 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-018-0283-5
Abstract: The purpose of the study was to evaluate the feasibility of conditioning regimen with sequential chemotherapy (FLAG-IDA), followed by Fludarabine (5 days) + Busulfan (3 days) by parallel analysis of patients with refractory acute myeloid leukemia (AML)… read more here.
Keywords: refractory aml; hematology; flag ida; study ... See more keywords
A review of treatment options employed in relapsed/refractory AML.
Sign Up to like & getrecommendations! Published in 2023 at "Hematology"
DOI: 10.1080/16078454.2023.2196482
Abstract: INTRODUCTION Acute myeloid leukemia [AML] is a heterogenous group of primary hematopoietic neoplasms arising from myeloid precursor cells. Up to 50% of patients failed to achieve remission with initial therapy and go on to develop… read more here.
Keywords: refractory aml; review treatment; aml; relapsed refractory ... See more keywords
Abstract CT103: Low-dose daunorubicin to target leukemia stem cells in newly diagnosed and relapsed/refractory AML
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Trials"
DOI: 10.1158/1538-7445.am2019-ct103
Abstract: Background: Chemotherapy-resistant leukemia stem cells (LSC) are responsible for disease relapse in many patients with Acute Myeloid Leukemia (AML). The Wnt/β-catenin and PI3K/Akt pathways are frequently activated in cancer and interact to stimulate stem cell… read more here.
Keywords: catenin; refractory aml; low dose; relapsed refractory ... See more keywords
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022008316
Abstract: Key Points • In relapsed or refractory AML, mutated NPM1 has no impact on the risk of relapse or death.• The addition of venetoclax to salvage treatment for NPM1-mutated AML is associated with improved outcomes. read more here.
Keywords: refractory aml; clinical outcomes; associated npm1; npm1 mutations ... See more keywords